Cargando…

Treatment of hepatitis C in special populations

Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis and hepatocellular carcinoma. In hemodialysis patients, the rate of HCV infection is high and is moreover associated with a poor prognosis. In liver transplantation patients with HCV infection, recurrent HCV infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suda, Goki, Ogawa, Koji, Morikawa, Kenichi, Sakamoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910474/ https://www.ncbi.nlm.nih.gov/pubmed/29299684 http://dx.doi.org/10.1007/s00535-017-1427-x

Ejemplares similares

Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment
por: Suda, Goki, et al.
Publicado: (2016)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
por: Morikawa, Kenichi, et al.
Publicado: (2018)

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication
por: Nakai, Masato, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids
por: Cai, Chengcong, et al.
Publicado: (2018)

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases
por: Sho, Takuya, et al.
Publicado: (2018)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2021)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
por: Nakai, Masato, et al.
Publicado: (2022)

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report
por: Umemura, Machiko, et al.
Publicado: (2021)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
por: Suda, Goki, et al.
Publicado: (2018)

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
por: Kawagishi, Naoki, et al.
Publicado: (2022)

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
por: Kubo, Akinori, et al.
Publicado: (2021)

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2020)

Small-molecule inhibitor cocktail promotes the proliferation of pre-existing liver progenitor cells
por: Fu, Qingjie, et al.
Publicado: (2022)

Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2021)

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
por: Ohara, Masatsugu, et al.
Publicado: (2018)

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
por: Sho, Takuya, et al.
Publicado: (2017)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing
por: Hirata, Koji, et al.
Publicado: (2019)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines()
por: Maehara, Osamu, et al.
Publicado: (2019)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Tokuchi, Yoshimasa, et al.
Publicado: (2021)

Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia
por: Yoshida, Sonoe, et al.
Publicado: (2021)

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2022)

Management of hepatitis B and C in special population
por: Kulkarni, Anand V, et al.
Publicado: (2021)

Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)
por: Kullak-Ublick, Gerd A., et al.
Publicado: (2014)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2023)

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis
por: Kanda, Tatsuo, et al.
Publicado: (2018)

Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis
por: Ogawa, Koji, et al.
Publicado: (2020)

Genetic Analyses of Cell-Free DNA in Pancreatic Juice or Bile for Diagnosing Pancreatic Duct and Biliary Tract Strictures
por: Nagai, Kosuke, et al.
Publicado: (2022)

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting
por: Sho, Takuya, et al.
Publicado: (2019)

Treatment of Chronic HCV Infection in Special Populations
por: Hoefs, John, et al.
Publicado: (2006)

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma
por: Ohara, Masatsugu, et al.
Publicado: (2023)

Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV)
por: Nakai, Masato, et al.
Publicado: (2015)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7rkv08rbd8chf6gflbugerujp6